eAppendix. Description of the Model
In the model, we classified the study population by 24 states based on age group, CD4 level, antiretroviral therapy (ART) status, and right of abode (non-local, local); young (aged 18-49), middle-aged (aged 50-64), older aged (aged >64); pre-ART CD4 ≥200/µl, pre-ART CD4 <200/µl, on ART CD4 ≥200/µl, on ART CD4 <200/µl):
Non-local, pre-ART: young and high CD4 (i=1); young and low CD4 (i=2); middle-aged and high CD4 (i=3); middle-aged and low CD4 (i=4); older-aged and high CD4 (i=5); older-aged and low CD4 (i=6); Local, pre-ART: young and high CD4 (i=7); young and low CD4 (i=8); middle-aged and high CD4 (i=9); middle-aged and low CD4 (i=10); older-aged and high CD4 (i=11); older-aged and low CD4 (i=12); Non-local, on ART: young and high CD4 (i=13); young and low CD4 (i=14); middle-aged and high CD4 (i=15); middle-aged and low CD4 (i=16); older-aged and high CD4 (i=17); older-aged and low CD4 (i=18); Local, on ART: young and high CD4 (i=19); young and low CD4 (i=20); middle-aged and high CD4 (i=21); middle-aged and low CD4 (i=22); older-aged and high CD4 (i=23); older-aged and low CD4 (i=24);
Over time, study populations progressed into older age groups, experienced CD4 decline before ART initiation, received ART, and experienced CD4 recovery after ART initiation. The rate was estimated from empirical clinical dataset of LTBI infected patients diagnosed with HIV between 2002 and 2013, with follow up time through mid-2017 (eTable 1).
CD4 200/µl is used as a threshold for defining states. In logistic regression model, the odds ratio (OR) between positive latent TB infection (LTBI) test results (defined as >5mm induration in tuberculin sensitivity testing) and CD4≥100/µL was 14, CD4≥200/µL was 3.02, CD4≥300/µL was 2.41, and CD4≥400/µL was 2.64.
Model equations

Time step = month
For HIV patients without LTBI
Waiting for the first LTBI test (never testers)
, * , * 1 , 
For HIV patients with LTBI
Waiting for the first LTBI test (never testers)
, * , * , 1 , * , * , 1 * * , ;
where TBdxntest[i] refers to TB reactivation rate for never testers with LTBI; 
Tested baseline LTBI positive, without LTBI treatment
Tested baseline LTBI positive, received LTBI treatment
where TBdxb_tx[i] refers to TB reactivation rate for patients tested LTBI positive received LTBI treatment; 
Available for the first followup LTBI test following negative baseline LTBI test result
eFigure 9. Incremental Cost-Effectiveness Ratio (ICER Plane) of LTBI Screening Strategies Under Different Coverage of Antiretroviral Therapy, LTBI Testing and Treatment, and TB treatment, 2017-2023
Screening strategies include strategy A: baseline screening ONLY; strategy B: baseline screening AND annual testing for risk groups; strategy C: baseline screening AND biennial testing for all until tested LTBI positive; strategy D: baseline screening AND at most three subsequent LTBI tests; and strategy E: baseline screening AND annual testing for all until tested LTBI positive. These strategies are under different coverage of antiretroviral therapy (ART), LTBI testing and treatment and TB treatment, including Scenario 1: baseline value for all; scenario 2: 100% coverage for all; scenario 3: baseline value for LTBI testing, and 100% for the rest; scenario 4: baseline value for LTBI testing and ART, and 100% for LTBI treatment and TB treatment; and scenario 5: baseline value for ART, and 100% for the rest. The incremental cost and quality-adjusted life-years (QALY) gained were compared with status quo (scenario E1).
